Sales & Earnings

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.

The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.

Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.

As big pharma braces for a new wave of patent expiries, we speak to two former industry chiefs – Novartis’s Joe Jimenez and Schering-Plough’s Fred Hassan – about the approach they took in similar circumstances.

Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.

Lupin has pushed the launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables

While Japan's largest pharma company reached a number of milestones last fiscal year, it is facing a number of challenges to revenues in 2023, for which it is looking to its core commercial portfolio and pipeline to help drive growth.

While Q1 earnings were nothing exciting, the German major highlighted that Pfizer’s decisions to return to the rights to Bavencio would boost performance in the near term, although competition from Seagen is on the horizon.

Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.